Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 321


Erratum: Scientists' Warning on Climate Change and Medicinal Plants.

Applequist WL, Brinckmann JA, Cunningham AB, Hart RE, Heinrich M, Katerere DR, van Andel T.

Planta Med. 2020 Jan;86(1):e1. doi: 10.1055/a-1113-1659. Epub 2020 Feb 6. No abstract available.


Medicinal Plant Analysis: A Historical and Regional Discussion of Emergent Complex Techniques.

Fitzgerald M, Heinrich M, Booker A.

Front Pharmacol. 2020 Jan 9;10:1480. doi: 10.3389/fphar.2019.01480. eCollection 2019. Review.


Topical Delivery of Niacinamide: Influence of Binary and Ternary Solvent Systems.

Zhang Y, Kung CP, Sil BC, Lane ME, Hadgraft J, Heinrich M, Sinko B.

Pharmaceutics. 2019 Dec 10;11(12). pii: E668. doi: 10.3390/pharmaceutics11120668.


Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW.

N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.


Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.

von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD.

Clin Cancer Res. 2019 Dec 2. doi: 10.1158/1078-0432.CCR-19-1069. [Epub ahead of print]


Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schöffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC.

Future Oncol. 2020 Jan;16(1):4251-4264. doi: 10.2217/fon-2019-0633. Epub 2019 Nov 22.


The ethnopharmacological literature: An analysis of the scientific landscape.

Yeung AWK, Heinrich M, Kijjoa A, Tzvetkov NT, Atanasov AG.

J Ethnopharmacol. 2020 Mar 25;250:112414. doi: 10.1016/j.jep.2019.112414. Epub 2019 Nov 18.


In vitro protective effects of plants frequently used traditionally in cancer prevention in Thai traditional medicine: An ethnopharmacological study.

Lumlerdkij N, Boonrak R, Booranasubkajorn S, Akarasereenont P, Heinrich M.

J Ethnopharmacol. 2020 Mar 25;250:112409. doi: 10.1016/j.jep.2019.112409. Epub 2019 Nov 18.


Scientists' Warning on Climate Change and Medicinal Plants.

Applequist WL, Brinckmann JA, Cunningham AB, Hart RE, Heinrich M, Katerere DR, van Andel T.

Planta Med. 2020 Jan;86(1):10-18. doi: 10.1055/a-1041-3406. Epub 2019 Nov 15. Review. Erratum in: Planta Med. 2020 Jan;86(1):e1.


Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.

Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.


Best practice in research - Overcoming common challenges in phytopharmacological research.

Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, Pezzuto JM, Viljoen A.

J Ethnopharmacol. 2020 Jan 10;246:112230. doi: 10.1016/j.jep.2019.112230. Epub 2019 Sep 14. Review.


Herbal medicine: Who cares? The changing views on medicinal plants and their roles in British lifestyle.

Lazarou R, Heinrich M.

Phytother Res. 2019 Sep;33(9):2409-2420. doi: 10.1002/ptr.6431. Epub 2019 Jul 16.


KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15.


Comprehensive HPTLC fingerprinting as a tool for a simplified analysis of purity of ginkgo products.

Frommenwiler DA, Booker A, Vila R, Heinrich M, Reich E, Cañigueral S.

J Ethnopharmacol. 2019 Oct 28;243:112084. doi: 10.1016/j.jep.2019.112084. Epub 2019 Jul 12.


Health care professionals' personal and professional views of herbal medicines in the United Kingdom.

Bhamra SK, Slater A, Howard C, Heinrich M, Johnson MRD.

Phytother Res. 2019 Sep;33(9):2360-2368. doi: 10.1002/ptr.6418. Epub 2019 Jul 7.


Structures, dipole moments and excited state lifetime of isolated 4-cyanoindole in its ground and lowest electronically excited singlet states.

Hebestreit ML, Schneider M, Lartian H, Betz V, Heinrich M, Lindic M, Choi MY, Schmitt M.

Phys Chem Chem Phys. 2019 Jul 10;21(27):14766-14774. doi: 10.1039/c9cp01618j.


Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Jul;121(3):281. doi: 10.1038/s41416-019-0487-5.


Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL.

Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006.


Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.

Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC.

Clin Sarcoma Res. 2019 May 7;9:7. doi: 10.1186/s13569-019-0117-2. eCollection 2019.


Unblocking High-Value Botanical Value Chains: Is There a Role for Blockchain Systems?

Heinrich M, Scotti F, Booker A, Fitzgerald M, Kum KY, Löbel K.

Front Pharmacol. 2019 Apr 24;10:396. doi: 10.3389/fphar.2019.00396. eCollection 2019.

Supplemental Content

Loading ...
Support Center